Saturday , July 21 2018
Home / Resources / Videos / Cyrus Desouza, MBBS, Q8: Cycloset – A New “Old” Drug Surprisingly Underused

Cyrus Desouza, MBBS, Q8: Cycloset – A New “Old” Drug Surprisingly Underused

Aug 26, 2013

Dr. Cyrus Desouza, MBBS, discusses cycloset, a new formulation of bromocriptine which has actually been around a long time. It has a similar story to metformin in that it’s been around a while so part of the reason it’s not more prescribed, he believes, is because it’s not a brand-new drug. Cycloset is one of the few drugs not requiring a CV trial separately because the work had already been done. There’s also been evidence of some CV benefit. One issue that comes up occasionally in his work at the VA, is that cycloset can interfere with psychiatric meds so you have to be careful prescribing. It is useful as an add-on therapy, possibly with metformin, because cycloset alone doesn’t have enough efficacy as a primary drug.

Dr. Desouza is currently Professor and Chief of the Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine at the University of Nebraska Medical Center. He is also the Director of the Diabetes and Obesity Program for the VA Nebraska-Western Iowa Healthcare System (NWIHCS). He is a board-certified clinical endocrinologist with research interests related to cardiovascular disease in insulin resistance and diabetes and improving outcomes in diabetes and obesity.

Dr. Desouza received his medical degree from St. Johns Medical College, Bangalore, India. He completed a rotating internship at St. Johns Medical College, Bangalore, India, senior house officer, internal medicine, Nair Hospital, Topiwala National Medical College, Bombay, India, residency, internal medicine, St. Barnabas Hospital, Bronx, New York, and a fellowship in the Division of Endocrinology, Diabetes and Metabolism at Tulane University, New Orleans, Louisiana.

Dr. Desouza is a member of numerous professional organizations including the American Diabetes Association, American College of Clinical Endocrinologists, The Endocrine Society, and American College of Physicians. He currently serves on the National Professional Practice Committee of the American Diabetes Association. He is also an editorial advisor for the Diabetes and Endocrinology Editorial Advisory Board for WebMD, LLC. He is a member of the editorial board for Diabetes Care as well as the Journal of Diabetes and its Complications. He is also a reviewer for the Journal of Endocrine PracticeDiabetes CareJCEMNature ReviewsEndocrinologyTranslation Research, and Clinical Chemistry.

Dr. Desouza has authored and co-authored several articles in major journals and presented at national meetings. He is the PI for several grants including a VA Merit Review grant looking at glycemic control. He is a site PI and an ancillary study committee member for a large NIH study: The Glycemic Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE) which is a national study comparing current medications and protocols used in diabetes treatment for an overall assessment of what is more effective. He is also the Vice Chair of the ancillary studies committee in a large NIH trial using Vitamin D to prevent type 2 diabetes (D2d) in people with pre-diabetes.